Q3 Interim Report November-January 2023/2024

UPPSALA, SE / ACCESSWIRE / March 14, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Several new commercial agreements signed and evidence that DiviTum TKa significantly improves clinical routines in the USA.

SEK t	Q3 23/24	Q3 22/23	May-Jan 23/24	May-Jan 22/23	Full year 22/23
Net sales	1,075	926	5,391	2,432	3,383
Operating profit (loss)	-27,848	-29,277	-85,355	-73,250	-110,457
Earnings per share, after dilution	-0.44	-0.64	-1.66	-2.33	-3.17
Number of shares at the end of the period	84,055,560	45,741,394	84,055,560	45,741,394	45,741,394
Cash and cash equivalents at the end of the period	105,238	145,150	105,238	145,150	114,327
Cash flow from operating activities	-22,760	-23,748	-89,324	-64,905	-94,640
Average number of employees	37	33	37	29	31

Significant events during the third quarter